CLINICAL_TRIALS ClinicalTrials.gov record update

3T: a Phase II Single Arm Open Label Study of Tucatinib Combined with Trastuzumab and TAS-102 in Molecularly Selected Patients with HER2+ Metastatic Colorectal Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05356897
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:13.128703+00:00
Published At: 2024-09-19T00:00:00+00:00
Record Updated At: 2024-09-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Rectal Adenocarcinoma", "Stage IV Colon Cancer AJCC V8", "Stage IV Colorectal Cancer AJCC V8", "Stage IV Rectal Cancer AJCC V8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-09-19"
protocolSection.identificationModule.nctId: "NCT05356897"
protocolSection.identificationModule.officialTitle: "3T: a Phase II Single Arm Open Label Study of Tucatinib Combined with Trastuzumab and TAS-102 in Molecularly Selected Patients with HER2+ Metastatic Colorectal Cancer"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.